SG3 Management’s Five Prime Therapeutics FPRX Stock Holding History
Bought
Maintained
Sold
SG3 Management's FPRX Position: Q2 2021 in Review
SG3 Management sold out of Five Prime Therapeutics (FPRX) in Q2 2021, closing a stake of 10,000 shares — an estimated $377K sold.
SG3 Management first reported a position in FPRX in Q1 2021 and held it in 1 quarter. The position peaked at $377K in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- SG3 Management reported no remaining Five Prime Therapeutics position as of Q2 2021 after selling out during the quarter.
- SG3 Management sold 10,000 Five Prime Therapeutics shares in Q2 2021, an estimated $377K.
- SG3 Management first reported a position in Five Prime Therapeutics in Q1 2021 and held it in 1 quarter.
- SG3 Management's Five Prime Therapeutics position peaked at $377K in Q1 2021.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics as of Q2 2021.
Based on SG3 Management's 13F filing for Q2 2021, filed 16 Aug 2021.